Excited to share new work @NEJM:
Drug prices are a major concern for Americans. We describe the many levers policymakers have—beyond price negotiation—to reduce the cost burden on patients, while maintaining incentives for the innovation society needs.https://www.nejm.org/doi/full/10.1056/NEJMhpr1911004?query=TOC …
-
-
The central insight is that America's drug market is anything but a traditional free market. Lawmakers have constructed every aspect of the system—and thus have many options, beyond price negotiation, to change the calculus for drug innovation & the costs to patients.
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.